MAPT and Alzheimer disease: Of particular interest are the plasma assays for p-tau species, which have shown excellent discriminatory ability in research cohorts, distinguishing between cognitive impaired AD, preclinical AD, other neurodegenerative disorders and healthy controls.16, 21